They observed that after the administration of COR in conjunction with a TIGIT inhibitor (an ICI), there was an increase in the number of dendritic cells infiltrating the tumor and showing an increase in the presentation of tumor antigens to CD8+ and CD4+ T cells while decreasing their interaction with Tregs promoting antitumor immunity. The gene discussed is CD8A; the disease is neoplasm.